Soft Tissue Sarcoma Market

In April 2026, Immutep announced that the FDA had granted Orphan Drug Designation to eftilagimod alfa for STS. Earlier, in January 2026, Intensity Therapeutics reported enrollment of 21 patients in the Phase III INVINCIBLE-3 trial evaluating INT230-6 in metastatic STS before a temporary enrollment pause related to funding constraints.

These developments highlight continued investment in therapies capable of addressing substantial unmet needs across different STS subtypes and treatment settings.

Soft Tissue Sarcoma Epidemiology Outlook

DelveInsight’s epidemiological analysis indicates that the United States recorded more than 13,500 incident STS cases in 2025, representing the highest number among the 7MM markets. The overall incidence is anticipated to rise through 2036, reinforcing the need for improved diagnosis and therapeutic options.

The epidemiology assessment covers the period from 2022 to 2036 and evaluates total incident cases, gender-specific cases, type-specific cases, age-specific cases, stage-specific cases, extremity-specific cases, and total treated cases. This detailed segmentation provides insight into the evolving patient population and potential treatment demand across major markets.

Explore key pipeline therapies shaping the future of soft tissue sarcoma treatment - https://www.delveinsight.com/report-store/soft-tissue-sarcoma-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Conclusion

The soft tissue sarcoma market is entering a period of meaningful transformation as increasing disease recognition, deeper biological understanding, and advances in precision medicine create new opportunities for therapeutic development. The expanding pipeline of cell therapies, intratumoral treatments, targeted agents, and immune-based combinations could significantly reshape the treatment paradigm over the coming decade. With the United States continuing to represent the largest market and STS incidence expected to rise through 2036, substantial unmet needs remain. Emerging therapies such as TBI-1301, INT230-6, ZEPZELCA, and Fibromun may play an important role in addressing these gaps and supporting continued market growth.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Abhishek kumar